RCT/extended follow-up | Lenvatinib plus pembrolizumab vs. sunitinib in patients with advanced renal cell carcinoma

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study – The Lancet Oncology (link to abstract – $ for full-text)

Original Study: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

NEW: In extended FU of the CLEAR trial (+7 mo), median PFS was 23·3 mo (95% CI 20·8–27·7) with first-line lenvatinib + pembrolizumab and 9·2 mo (6·0–11·0) with sunitinib (stratified HR 0·42, 95% CI 0·34–0·52) in pts w/ advanced renal cell carcinoma. #rccsmhttps://t.co/gbwBIIqSK8 pic.twitter.com/78OijM9Rtm

— The Lancet Oncology (@TheLancetOncol) February 28, 2023